Barclays lowered the firm’s price target on Anteris Technologies (AVR) to $17 from $22 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect its recent financing. Now that its financing risk is reduced, Anteris is well positioned to execute on a clinical program to support its “differentiated” balloon-expandable transcatheter heart valve system platform, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVR:
- Largest borrow rate increases among liquid names
- Anteris Technologies price target lowered to $15 from $20 at Lake Street
- Anteris Technologies Secures $320 Million for PARADIGM Trial
- Ten new option listings and two option delistings on January 22nd
- Anteris Technologies Announces Major Equity Offering and Medtronic Deal